Plain-English translation of NCT06904729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether CAR-T cell therapy — a treatment that uses specially trained immune cells — can safely and effectively treat children with lupus nephritis (a serious kidney disease caused by lupus) that has not responded well to standard medications. Researchers will give children in this trial infusions of these engineered immune cells and closely monitor how well the treatment works and how the children's bodies respond to it.
Many children with lupus nephritis don't get better even after trying multiple standard medications, which can cause serious side effects and damage to the kidneys. This trial explores whether this new immune cell therapy could offer a better option that works more effectively and causes fewer of the harmful side effects associated with traditional treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive infusions of CAR-T cells (specially prepared immune cells made from your own blood). The research team will collect some of your blood cells, send them to a lab where they will be engineered, and then give them back to you through an infusion. You will have follow-up visits where doctors will monitor how well the treatment is working, check for side effects, and measure changes in your kidney function and lupus activity over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China